BioLife Solutions Sees 29% Revenue Surge, $25M EBITDA and New Quine Deal
BioLife Solutions reported a 29% revenue increase to $96 million in 2025 with adjusted EBITDA rising to $25 million, or 26% of revenue, up from 18% in 2024. The company faces a 2–3 point gross margin headwind from bag yield issues through Q4 2026 while expanding via a strategic Quine partnership.
1. Q4 2025 Financial Results
BioLife Solutions reported revenue of $96 million in 2025, a 29% increase from the prior year, and achieved adjusted EBITDA of $25 million, representing 26% of revenue compared to 18% in 2024.
2. Margin Headwinds from Bag Yield Issues
A 2–3 point gross margin headwind from bag yield challenges will persist through Q4 2026, with a solution requiring a 90-day customer notification to drive improvements.
3. Strategic Partnership and Market Position
The company has embedded its bioprocessing products in 16 approved CAR-T therapies and over 250 U.S. trials and has expanded its offerings through a distribution and product development agreement with Quine Limited.
4. Growth Outlook and Therapy Approvals
BioLife anticipates up to five unique therapy approvals over the next 12 months, which, alongside cross-selling initiatives, could unlock additional upside beyond base revenue projections.